Your browser is no longer supported. Please, upgrade your browser.
Settings
KDMN Kadmon Holdings, Inc. daily Stock Chart
KDMN [NYSE]
Kadmon Holdings, Inc.
Index- P/E- EPS (ttm)-0.70 Insider Own0.10% Shs Outstand158.03M Perf Week-10.27%
Market Cap766.95M Forward P/E82.81 EPS next Y0.06 Insider Trans57.93% Shs Float144.07M Perf Month9.51%
Income-96.30M PEG- EPS next Q-0.13 Inst Own88.60% Short Float13.39% Perf Quarter22.28%
Sales11.60M P/S66.12 EPS this Y17.70% Inst Trans8.21% Short Ratio7.98 Perf Half Y5.36%
Book/sh0.61 P/B7.74 EPS next Y110.20% ROA-50.10% Target Price- Perf Year121.60%
Cash/sh0.91 P/C5.18 EPS next 5Y- ROE-107.90% 52W Range1.98 - 5.50 Perf YTD4.19%
Dividend- P/FCF- EPS past 5Y19.70% ROI-72.30% 52W High-14.18% Beta1.47
Dividend %- Quick Ratio6.40 Sales past 5Y-44.30% Gross Margin83.90% 52W Low138.38% ATR0.30
Employees115 Current Ratio6.40 Sales Q/Q9952.20% Oper. Margin- RSI (14)48.31 Volatility5.38% 6.27%
OptionableYes Debt/Eq0.00 EPS Q/Q-875.10% Profit Margin- Rel Volume0.75 Prev Close4.81
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.42M Price4.72
Recom1.70 SMA20-1.46% SMA503.00% SMA20015.87% Volume1,820,258 Change-1.87%
May-19-20Initiated Raymond James Outperform $7
Jan-10-20Initiated Nomura Buy $10
Feb-26-19Upgrade Citigroup Neutral → Buy
Oct-17-18Upgrade WBB Securities Sell → Hold $2.90
Mar-16-17Upgrade WBB Securities Sell → Hold $3.25
Mar-14-17Initiated Piper Jaffray Overweight
Jun-23-20 08:00AM  
Jun-11-20 08:00AM  
Jun-08-20 02:22AM  
Jun-05-20 04:15PM  
Jun-01-20 09:56AM  
May-27-20 08:00AM  
May-21-20 01:35PM  
07:25AM  
May-19-20 04:08PM  
May-11-20 06:52AM  
May-10-20 10:50AM  
May-07-20 04:14PM  
Apr-14-20 09:20AM  
07:59AM  
Mar-13-20 04:15PM  
Mar-09-20 01:57PM  
Mar-05-20 04:14PM  
Feb-23-20 12:29PM  
Jan-22-20 09:33AM  
Jan-10-20 04:15PM  
Jan-06-20 08:34AM  
Dec-26-19 08:40AM  
08:00AM  
Dec-12-19 07:38PM  
Dec-07-19 08:35AM  
Dec-03-19 08:00AM  
Nov-22-19 12:13PM  
Nov-18-19 04:15PM  
08:15AM  
Nov-13-19 08:50PM  
04:25PM  
Nov-12-19 10:39AM  
07:20AM  
Nov-11-19 04:24PM  
Nov-08-19 10:57AM  
Nov-07-19 04:15PM  
04:15PM  
Oct-21-19 04:14PM  
Oct-07-19 03:19PM  
Oct-03-19 08:00AM  
Sep-23-19 08:00AM  
Sep-17-19 04:15PM  
Sep-07-19 12:19PM  
Sep-03-19 08:06AM  
Aug-30-19 04:15PM  
Aug-23-19 11:10AM  
Aug-14-19 09:10AM  
Aug-13-19 08:00AM  
Aug-05-19 04:14PM  
Aug-01-19 10:33AM  
Jul-18-19 03:47PM  
Jul-11-19 11:19AM  
Jul-10-19 05:51PM  
Jul-09-19 04:14PM  
Jun-23-19 09:44PM  
May-29-19 09:00AM  
May-17-19 03:45PM  
May-09-19 04:14PM  
Apr-03-19 09:00AM  
Apr-01-19 04:15PM  
Mar-22-19 04:15PM  
Mar-13-19 11:30AM  
09:00AM  
Mar-07-19 04:17PM  
Feb-11-19 04:15PM  
Feb-07-19 04:15PM  
Jan-28-19 08:15AM  
Jan-23-19 04:15PM  
Jan-04-19 04:15PM  
Dec-27-18 04:15PM  
Dec-03-18 10:00AM  
Nov-29-18 09:00AM  
Nov-28-18 08:10AM  
Nov-09-18 04:20PM  
Nov-07-18 09:00AM  
Nov-06-18 08:00AM  
Nov-01-18 09:00AM  
Oct-25-18 08:00AM  
Oct-24-18 04:15PM  
Oct-18-18 09:20AM  
Oct-17-18 09:00AM  
Aug-29-18 09:00AM  
Aug-27-18 07:40AM  
Aug-23-18 11:39AM  
Aug-09-18 04:15PM  
Jun-21-18 08:25AM  
Jun-15-18 09:00AM  
Jun-14-18 04:15PM  
Jun-12-18 12:45PM  
Jun-11-18 07:55PM  
04:01PM  
May-31-18 09:00AM  
May-17-18 09:02AM  
May-08-18 04:15PM  
May-01-18 07:35AM  
Apr-10-18 08:00AM  
Mar-06-18 04:15PM  
Feb-26-18 07:10AM  
Feb-22-18 06:45PM  
Feb-13-18 07:37PM  
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleoside Inhibitor to treat hepatitis; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. The company was founded in 2010 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Waksal HarlanPresident, CEOMar 13Buy2.9316,00046,811152,945Mar 16 08:37 AM
Schwalm CynthiaDirectorMar 12Buy3.2431,000100,39331,000Mar 12 05:57 PM
Waksal HarlanPresident, CEOMar 11Buy3.9612,60049,859136,945Mar 11 04:22 PM
PERCEPTIVE ADVISORS LLCFormer 10% ownerNov 18Buy3.401,470,5884,999,99914,636,334Nov 18 07:57 AM